RayKnowChina Research Map
Shortlist

Jiangmen

Jiangmen Central Hospital

江门市中心医院

Listed for 4 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Jiangmen Central Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌1 paper led
  2. Lung cancer肺癌17 papers led1 open trial led
  3. Osteosarcoma骨肉瘤0 papers led
  4. Beta thalassaemiaβ 地中海贫血2 papers led

Not listed for: Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Jiangmen for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyImmunotherapy
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study.2025Cancer immunology, immunotherapy : CIIFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  2. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  3. Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02250599Study sitePhase 2Start 2014-08
More papers found outside PubMed (not counted)10
  1. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  3. A prospective multicenter trial of dose escalation for weekly gemcitabine concurrent with intensity-modulated radiotherapy following cisplatin and gemcitabine induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma2024Journal of Clinical Oncologyconference-abstract
  4. Semi-supervised segmentation for primary nasopharyngeal carcinoma tumors using local-region constraint and mixed feature-level consistency2024Engineering Applications of Artificial Intelligencearticle
  5. A retrospective analysis of tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy plus nimotuzumab in patients with high-risk nasopharyngeal carcinoma.2023Journal of Clinical Oncologyconference-abstract
  6. SMTF: Sparse transformer with multiscale contextual fusion for medical image segmentation2023Biomedical Signal Processing and Controlarticle
  7. 153P Neoadjuvant therapy with tislelizumab plus chemotherapy followed by concurrent chemoradiotherapy in patients with stage IVa nasopharyngeal carcinoma: A single-arm, phase II trial2022Immuno-Oncology Technologyarticle
  8. The Clinicopathological Characteristics, MRI Features, And Radiation Dose Of Radio-Induced Brain Necrosis In Nasopharyngeal Carcinoma Patients2022Research Squarepreprint
  9. The clinicopathological characteristics, MRI features, and radiation dose of radio-induced brain necrosis in nasopharyngeal carcinoma patients2022Research Squarepreprint
  10. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 17 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.07%.

Papers led
17
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 6620242025: 662025

1 hospital in Jiangmen for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07583550

    Age 18 years to 75 years (registered criteria)

    Led by Jiangmen Central HospitalJiangmen

  2. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  3. Recruiting
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07227597

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou

  4. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  5. Recruiting
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06862869

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi

  6. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  7. Recruiting
    A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06496490

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi

  8. Recruiting
    Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
    Phase
    Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05334277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Foshan, Guangzhou, Hangzhou, Jiangmen, Nanchang, Shenyang, Urumqi, Wuhan, Xi'an, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led17
  1. M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLC.2025Cancer control : journal of the Moffitt Cancer CenterFree full text
  2. Collaborative assessment of the risk of postoperative progression in early-stage non-small cell lung cancer: a robust federated learning model.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  3. Development and functional validation of a disulfidoptosis-related gene prognostic model for lung adenocarcinoma based on bioinformatics and experimental validation.2025Frontiers in immunologyFree full text
  4. ZWINT down-regulated by miR-495-3p inhibited lung metastasis of breast cancer by blocking p38 MAPK signaling pathway activation.2025Human cellFree full text
  5. A combination of hepatic leukemia factor and circulating tumor cells serve as effective biomarkers for lung adenocarcinoma prognosis.2025PeerJFree full text
  6. A generalized heterogeneous federated model for identifying patients with postoperative progression of early-stage non-small cell lung cancer.2025Scientific reportsFree full text
  7. Multi‑omics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.2024BMC cancerFree full text
  8. Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response.2024BMC cancerFree full text
  9. Multimodal deep learning radiomics model for predicting postoperative progression in solid stage I non-small cell lung cancer.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  10. The COP9 signalosome stabilized MALT1 promotes Non-Small Cell Lung Cancer progression through activation of NF-κB pathway.2024Cell biology and toxicologyFree full text
  11. Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer.2024Frontiers in immunologyFree full text
  12. Causal association between immune cells and lung cancer risk: a two-sample bidirectional Mendelian randomization analysis.2024Frontiers in immunologyFree full text
  13. Commentary on: The actin bundling activity of ITPKA mainly accounts for its migration-promoting effect in lung cancer cells.2023Bioscience reportsFree full text
  14. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.2022Annals of palliative medicine
  15. ARHGEF37 overexpression promotes extravasation and metastasis of hepatocellular carcinoma via directly activating Cdc42.2022Journal of experimental & clinical cancer research : CRFree full text
  16. The pathological tissue expression pattern and clinical significance of m6A-regulatory genes in non-small cell lung cancer.2022The journal of gene medicine
  17. A CT-based deep learning model for subsolid pulmonary nodules to distinguish minimally invasive adenocarcinoma and invasive adenocarcinoma.2021European journal of radiology
All its trials on ClinicalTrials.gov, any status15
  1. Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerRecruitingNCT07583550Lead sponsorPhase 2Start 2026-07
  2. A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingNCT07227597Study sitePhase 1/Phase 2Start 2026-01
  3. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT07222566Study sitePhase 3Start 2026-01
  4. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Study sitePhase 3Start 2026-04
  5. Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruitingNCT06862869Study siteStart 2025-04
  6. A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyRecruitingNCT07010263Study sitePhase 3Start 2025-06
  7. A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityRecruitingNCT06496490Study sitePhase 2Start 2024-08
  8. Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Study sitePhase 2Start 2022-05
  9. A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLCActive, not recruitingNCT06883630Study sitePhase 1Start 2025-03
  10. A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT07005336Study sitePhase 2Start 2025-01
  11. Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentActive, not recruitingNCT06502977Study sitePhase 2Start 2024-08
  12. A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerActive, not recruitingNCT06012435Study sitePhase 3Start 2024-02
  13. Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerActive, not recruitingNCT05740566Study sitePhase 3Start 2023-05
  14. TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerStatus unknownNCT05284994Study sitePhase 1/Phase 2Start 2022-03
  15. Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04379635Study sitePhase 3Start 2020-05

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Jiangmen for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Jiangmen for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

江门市中心医院

Jiangmen Central Hospital

江门

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Renji Hospital

Suggest a correctionDownload the data